---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-148822"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2021-12-13T23:59:59+00:00"
generated_at: "2026-06-28T01:36:12.343488+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Altimmune appoints Richard Eisenstadt as CFO effective Dec 31, 2021

## Summary
- William Brown resigns as CFO effective Dec 31, 2021 to pursue other opportunities; no disagreement.
- Richard Eisenstadt appointed CFO effective Dec 31; annual salary $425,000, target bonus 40%, signing bonus $120,000.
- Eisenstadt receives 150,000 stock options and 50,000 RSUs; options vest 25% at one year, balance over 36 months.
- Eisenstadt previously CFO at Aytu BioPharma and Neos Therapeutics; raised over $340M in financings.

## SEC filing metadata
- accession: 0001104659-21-148822
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2021-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/tm2135141d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-148822
- JSON: https://secwatch.observer/filing/0001104659-21-148822.json
- Plain text: https://secwatch.observer/filing/0001104659-21-148822.txt

## Key facts
- Executive change
  William Brown resigned as Chief Financial Officer at Altimmune, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm
- Executive change
  Richard I. Eisenstadt was appointed as Chief Financial Officer at Altimmune, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.